IndustryCompany release
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
The Nasdaq-listed company reports positive Q3 adjusted free cash flow of $4.1 million, helped by borrowing, while raising planned customer-acquisition spend for its IM8 supplement brand.
Prenetics Global (NASDAQ: PRE) said in its Q3 2026 shareholder letter, published in November 2026, that Adjusted Free Cash Flow reached $4.1 million. The company noted that the figure was helped by $31.6 million of net drawdowns on its General Catalyst facility.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Prenetics Global Ltd ↗
Article written by VigiEye from the official source (Prenetics Global Ltd). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
🇺🇸 Interpace Biosciences, Inc. (IDXG) · Tue 17 Nov 2026
Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer
🇺🇸 Viatris Inc (VTRS) · Tue 17 Nov 2026